Literature DB >> 14552587

Modeling the interaction of paclitaxel with beta-tubulin.

Michael T G Ivery1, Tuyet Le.   

Abstract

The natural product cytotoxic agent, paclitaxel, partly induces cell death through its ability to disrupt mitosis by binding to the microtubule protein beta-tubulin. Structural characterization of the paclitaxel-beta-tubulin complex, a first stage in the design of new antimitotics, has been complicated by contradictory observations obtained from different experimental techniques [electron crystallography, fluorescence resonance energy transfer (FRET), and photo-affinity labeling (PAL)] used to examine the complex. In this study we have used a range of molecular modeling techniques including restrained conformational searching and computer-assisted docking to propose that these contradictions may be resolved by the hypothesis that the nature of the interaction of paclitaxel with beta-tubulin depends on the physical form of the tubulin examined. In particular, our analysis identified a binding mode that is consistent with available data for the interaction of paclitaxel with beta-tubulin in polymerized tubulin or microtubules. This orientation is characterized by an alternate conformation (inverted orientation of side chains) and inverted orientation of the taxane core of paclitaxel within its tubulin binding site compared with the electron crystallographic structure. The proposed structure, however, is only marginally consistent with electron crystallographic data for the interaction of paclitaxel with beta-tubulin in Zn-induced tubulin sheets. Similarly, the electron crystallographic structure shows poor correlation with FRET, solid-state NMR, and some observed SAR relationships for paclitaxel interacting with polymerized tubulin or microtubules. These observations suggest to us that the interaction of paclitaxel with Zn-induced tubulin sheets may not reflect paclitaxel's interaction with tubulin in microtubules and hence may not be an appropriate guide for rational drug design programs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14552587     DOI: 10.3727/000000003108748568

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  6 in total

1.  Verteporfin enhances the sensitivity of LOVO/TAX cells to taxol via YAP inhibition.

Authors:  Ganggang Shi; Hao Wang; Hongqiu Han; Jianchen Gan; Hui Wang
Journal:  Exp Ther Med       Date:  2018-07-16       Impact factor: 2.447

2.  Molecular dynamics simulation and density functional theory studies on the active pocket for the binding of paclitaxel to tubulin.

Authors:  Sichuan Xu; Shaoming Chi; Yi Jin; Qiang Shi; Maofa Ge; Shu Wang; Xingkang Zhang
Journal:  J Mol Model       Date:  2011-05-03       Impact factor: 1.810

3.  Integrated Network Pharmacology Approach for Drug Combination Discovery: A Multi-Cancer Case Study.

Authors:  Antonio Federico; Michele Fratello; Giovanni Scala; Lena Möbus; Alisa Pavel; Giusy Del Giudice; Michele Ceccarelli; Valerio Costa; Alfredo Ciccodicola; Vittorio Fortino; Angela Serra; Dario Greco
Journal:  Cancers (Basel)       Date:  2022-04-18       Impact factor: 6.575

4.  The bioactive Taxol conformation on beta-tubulin: experimental evidence from highly active constrained analogs.

Authors:  Thota Ganesh; Rebecca C Guza; Susan Bane; Rudravajhala Ravindra; Natasha Shanker; Ami S Lakdawala; James P Snyder; David G I Kingston
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-28       Impact factor: 11.205

Review 5.  Long non-coding RNAs regulation of therapeutic resistance.

Authors:  Susan Tsang; Tajhal Patel; Jason T Yustein
Journal:  Cancer Drug Resist       Date:  2019-09-19

6.  Proton pump inhibitors can reverse the YAP mediated paclitaxel resistance in epithelial ovarian cancer.

Authors:  Jing He; Xiao-Yan Shi; Zhi-Min Li; Xiao-Hua Pan; Ze-Lian Li; Ying Chen; Shi-Jie Yan; Lan Xiao
Journal:  BMC Mol Cell Biol       Date:  2019-11-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.